embecta to Participate in Investor Events
Get Alerts EMBC Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.8%
Revenue Growth %: +1.3%
Join SI Premium – FREE
PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:
2025 Goldman Sachs Tenth Annual Leveraged Finance and Credit Conference
- Management will host one-on-one investor meetings on Thursday, May 29, 2025, at Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA.
2025 Jefferies Global Healthcare Conference
- Management will host a fireside session on Thursday, June 5, 2025, at 4:55 p.m. EDT, at the Marriott Marquis, New York City.
2025 Goldman Sachs 46th Annual Global Healthcare Conference
- Management will host a fireside session on Tuesday, June 10, 2025, at 1:20 p.m. EDT, at the Loews Miami Beach Hotel, Miami, FL.
2025 Truist Securities MedTech Conference
- Management will host one-on-one investor meetings on Tuesday, June 17, 2025, at the InterContinental, Boston, MA.
About embecta
embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
Contacts:
| Media Christian Glazar Sr. Director, Corporate Communications 908-821-6922 Contact Media Relations | Investors Pravesh Khandelwal VP, Head of Investor Relations 551-264-6547 Contact IR |
Source: Embecta Corp.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Inbank Financial Calendar for 2027
- T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
- OSB GROUP PLC Announces Cash Tender Offers for its £300,000,000 Fixed Rate Resetting Notes due 7 September 2028 and £400,000,000 Fixed Rate Resetting Notes due 16 January 2030
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Goldman Sachs, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share